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Several studies have shown comparable survival outcomes with different graft sources, but the relative
resource needs of hematopoietic cell transplantation (HCT) by graft source have not been well studied. We
compared total hospital length of stay in the ﬁrst 100 days after HCT in 1577 patients with acute leukemia in
remission who underwent HCT with an umbilical cord blood (UCB), matched unrelated donor (MUD), or
mismatched unrelated donor (MMUD) graft between 2008 and 2011. To ensure a relatively homogenous
study population, the analysis was limited to patients with acute myelogenous leukemia and acute
lymphoblastic leukemia in ﬁrst or second complete remission who underwent HCT in the United States. To
account for early deaths, we compared the number of days alive and out of the hospital in the ﬁrst 100 days
post-transplantation. For children who received myeloablative conditioning, the median time alive and out of
the hospital in the ﬁrst 100 days was 50 days for single UCB recipients, 54 days for double UCB recipients, and
60 days for MUD bone marrow (BM) recipients. In multivariate analysis, use of UCB was signiﬁcantly asso-
ciated with fewer days alive and out of the hospital compared with MUD BM. For adults who received
myeloablative conditioning, the median time alive and out of the hospital in ﬁrst 100 days was 52 days for
single UCB recipients, 55 days for double UCB recipients, 69 days for MUD BM recipients, 75 days for MUD
peripheral blood stem cell (PBSC) recipients, 63 days for MMUD BM recipients, and 67 days for MMUD PBSC
recipients. In multivariate analysis, UCB and MMUD BM recipients had fewer days alive and out of the hospital
compared with recipients of other graft sources. For adults who received a reduced-intensity preparative
regimen, the median time alive and out of the hospital during the ﬁrst 100 days was 65 days for single UCBdgments on page 1826.
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K.K. Ballen et al. / Biol Blood Marrow Transplant 20 (2014) 1819e18271820recipients, 63 days for double UCB recipients, 79 days for MUD PBSC recipients, and 79 days for MMUD PBSC
recipients. Similar to the other 2 groups, receipt of UCB was associated with a fewer days alive and out of the
hospital. In conclusion, length of stay in the ﬁrst 100 days post-transplantation varies by graft source and is
longer for UCB HCT recipients. These data provide insight into the resource needs of patients who undergo
HCT with these various graft sources.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION consecutive allogeneic and autologous HCT to a statistical center at the
The use of alternative donors, such as unrelated umbilical
cord blood (UCB), haploidentical family members, and mis-
matched unrelated donors (MMUDs), allows patients
without an HLA-matched sibling or matched unrelated
donor (MUD) to proceed to hematopoietic cell trans-
plantation (HCT). Several studies have shown comparable
HCT survival outcomes with different graft sources [1-7];
however, data are limited on the costs and resource needs of
HCT performed using different graft sources.
Allogeneic HCT is a resource-intensive procedure, and
health care resource allocation is now being analyzed closely.
Khera et al. [8] and Preussler et al. [9] recently summarized
the trends in costs of HCT. In a study using a national claims
database of commercially insured population in the United
States, Majhail et al. [10] reported median costs associated
with allogeneic HCT of $203,026 in the ﬁrst 100 days post-
transplantation. The median total hospital length of stay
(LOS) was 31 days, with the initial transplantation hospital-
ization accounting for >75% of these early costs. Data on
costs and resource needs by graft source were not available.
The Minnesota group compared HCT-associated costs in the
ﬁrst 100 days between UCB recipients and matched related
donor graft recipients who received pretransplantation
conditioning with either a myeloablative conditioning (MAC)
or reduced-intensity conditioning (RIC) regimen [11,12]. The
median cost per day of survival (not including graft acqui-
sition) was $1016 for MAC matched related donor recipients,
$2082 for MAC UCB recipients, $612 for RIC matched related
donor recipients, and $1156 for RIC UCB recipients. In a
separate study, the same group reported greater blood
product use in patients receiving UCB grafts and patients
receiving a MAC regimen [13].
Information on the resource needs associated with the
different alternative graft sources obtained through a
multicenter studywill have important policy implications for
estimating costs and needs for resources, infrastructure, and
personnel. Previous studies of the costs associated with HCT
have been limited to single-center analyses and reﬂect
institutional practices speciﬁc to that institution. Further-
more, resource utilization in this population has not been
well described. Although the Center for International Blood
and Marrow Transplant Research (CIBMTR) does not collect
data on resource utilization and costs of HCT, it does capture
information on the total hospital LOS in the ﬁrst 100 days.
Given that hospitalization is the largest contributor to early
post-transplantation resource utilization, we compared LOS
in the ﬁrst 100 days in recipients of different graft sources in
a multicenter cohort. This information can aid trans-
plantation physicians and centers in planning for resource
allocation and utilization such as for hospital beds and
admissions.
PATIENTS AND METHODS
Data Source and Patients
The CIBMTR comprises a voluntary working group of more than 500
transplantation centers worldwide that contribute detailed data onMedical College of Wisconsin in Milwaukee and the National MarrowDonor
Program’s Coordinating Center in Minneapolis. Participating centers are
required to report all transplantations consecutively; compliance is moni-
tored by onsite audits. Patients are followed longitudinally, with yearly
follow-up. Computerized checks for errors, physicians’ review of submitted
data, and onsite audits of participating centers ensure data quality. Obser-
vational studies conducted by the CIBMTR are performed in compliance
with the HIPAA Privacy Rule as a public health authority and in compliance
with all applicable federal regulations pertaining to the protection of human
research participants as determined by continuous review of the National
Marrow Donor Program’s Institutional Review Board.
The study population comprised patients with acute myelogenous leu-
kemia (AML) or acute lymphoblastic leukemia (ALL) in ﬁrst or second
complete remission (CR) who underwent their ﬁrst allogeneic HCT in the
United States and were reported to the CIBMTR between 2008 and 2011. All
age groups and recipients of both MAC and RIC regimens were considered.
Graft sources included UCB and both 7/8 HLA-MMUD and 8/8 HLA-MUD
bone marrow (BM) and peripheral blood stem cells (PBSCs); HLA-matched
sibling donors were excluded. Owing to the small number of patients,
haploidentical HCT recipients were not included in this analysis. To obtain a
relatively homogenous group for comparison, we restricted our study
population to commonly used conditioning regimens. MAC regimens
included busulfan (Bu) þ cyclophosphamide (Cy)  other and Cy þ total
body irradiation (TBI) other. RIC regimens included TBIþ Cyþ ﬂudarabine
(Flu)  other, TBI þ Flu  other (no Cy), Bu þ Flu  other, and melphalan
(Mel) þ Flu  other. For the same reason, we excluded patients who had
received ex vivo T cell depletion as part of graft-versus-host disease (GVHD)
prophylaxis.Outcomes and Study Deﬁnitions
The primary objective of this study was to compare LOS in recipients of
HCT from different graft sources. LOS is captured by the CIBMTR as total days
of hospitalization (initial admission and any readmissions) between day
0 (day of transplantation) and day þ100 post-transplantation. Patients who
die early after transplantation have less time at risk for hospitalization and a
shorter LOS than those who survive to day þ100. To account for this asso-
ciation of early mortality with shorter hospitalization, in our analysis we
used the number of days alive and out of the hospital as the metric for
comparing LOS in ﬁrst 100 days. For patients who died within 100 days, we
evaluated the number of days of survival out of the hospital; for example,
the number of days alive and out of the hospital would be 0 days for a pa-
tient who died on day þ20 and had spent all 20 days in the hospital and
20 days for a patient who died on day þ40 and had spent 20 days in the
hospital. For patients who survived through day 100, we censored follow-up
at that time point; for example, the number of days alive and out of the
hospital would be 80 days for a patient who survived through dayþ100 and
had spent 20 days in the hospital. We also evaluated the proportion of days
alive and out of the hospital; the results for both analyses were similar, and
thus we present data only on the number of days alive and out of the hos-
pital. In addition, we performed a subset analysis in patients who survived
through day þ100. We also report 100-day overall survival in recipients of
the various graft sources. All outcomes were assessed from the date of HCT.
Given the differences in patient characteristics and transplantation
practices among adult and pediatric transplantation centers, We analyzed
pediatric (age 18 years) and adult (age >18 years) transplant recipients
separately. We also analyzed MAC and RIC regimen recipients separately,
given the variation in the time to neutrophil engraftment and consequently
LOS. We excluded patient groups with a sample size of <30 patients. Spe-
ciﬁcally, we excluded pediatric patients who received an RIC regimen, re-
cipients of haploidentical transplants, and recipients of some graft source
subcategories (eg, pediatric MUD PBSC, pediatric MMUD BM and PBSC, and
adult RIC MUD and MMUD BM). Thus, our ﬁnal study population comprised
1577 patients, who were analyzed in 3 separate groups: pediatric MAC HCT
recipients (single UCB, double UCB, andMUD BM), adult MAC HCT recipients
(single UCB, double UCB, MUD BM, MUD PBSC, MMUD BM, and MMUD
PBSC), and adult RIC HCT recipients (single UCB, double UCB, MUD PBSC, and
MMUD PBSC).
Table 1
Patient Characteristics
Characteristic Pediatric, MAC Regimen Adult, MAC Regimen Adult, RIC Regimen
Single UCB Double UCB MUD BM P
value
Single UCB Double UCB MUD BM MUD PBSC MMUD BM MMUD PBSC P
value
Single UCB Double UCB MUD PBSC MMUD
PBSC
P
value
Number of patients 219 80 69 65 146 92 297 42 126 16 188 160 77
Number of centers 54 32 30 19 45 38 68 25 53 9 43 48 36
Age at transplantation,
yr, median (range)
6 (<1-18) 12 (1-18) 9 (<1-18) <.001 45 (18-72) 33 (18-68) 41 (18-63) 42 (19-66) 35 (18-61) 41 (19-65) <.01 58 (19-70) 58 (19-72) 63 (21-78) 61 (23-73) <.01
Male sex 114 (52) 54 (68) 41 (59) .05 25 (38) 72 (49) 48 (52) 146 (49) 21 (50) 66 (52) .57 8 (50) 94 (50) 104 (65) 43 (56) .04
Recipient race <.01 <.01
White 172 (79) 64 (80) 57 (83) .01 48 (74) 106 (73) 86 (93) 276 (93) 36 (86) 110 (87) 13 (81) 153 (81) 154 (96) 68 (88)
Black 26 (12) 7 (9) 2 (3) 9 (14) 24 (16) 2 (2) 6 (2) 4 (10) 8 (6) 2 (13) 13 (7) 2 (1) 5 (6)
Other 11 (5) 8 (10) 2 (3) 7 (11) 13 (9) 2 (2) 11 (4) 1 (2) 7 (6) 1 (6) 18 (10) 0 2 (3)
Unknown 10 (5) 1 (1) 8 (12) 1 (2) 3 (2) 2 (2) 4 (1) 1 (2) 1 (1) 0 4 (2) 4 (3) 2 (3)
Karnofsky/Lansky
score 80
209 (95) 79 (99) 67 (97) .34 57 (88) 137 (94) 86 (93) 260 (88) 42 116 (92) .13 12 (75) 176 (94) 151 (94) 63 (82) <.01
Diagnosis <.01 .02 .08
AML 88 (40) 35 (44) 46 (67) 44 (68) 94 (64) 70 (76) 236 (79) 30 (71) 94 (75) 14 (88) 160 (85) 148 (93) 72 (94)
ALL 131 (60) 45 (56) 23 (33) 21 (32) 52 (36) 22 (24) 61 (21) 12 (29) 32 (25) 2 (13) 28 (15) 12 (8) 5 (6)
Disease status .08 .12 .10
CR1 111 (51) 34 (43) 42 (61) 45 (69) 87 (60) 61 (66) 217 (73) 27 (64) 85 (67) 13 (81) 131 (70) 129 (81) 60 (78)
CR2 108 (49) 46 (58) 27 (39) 20 (31) 59 (40) 31 (34) 80 (27) 15 (36) 41 (33) 3 (19) 57 (30) 31 (19) 17 (22)
HCT-CI score .07 .29 .09
0 178 (81) 61 (76) 48 (70) 22 (34) 59 (40) 30 (33) 107 (36) 21 (50) 51 (40) 8 (50) 53 (28) 55 (34) 16 (21)
1-2 29 (13) 15 (19) 11 (16) 16 (25) 49 (34) 34 (37) 94 (32) 6 (14) 45 (36) 3 (19) 68 (36) 48 (30) 23 (30)
3 12 (5) 4 (5) 10 (14) 27 (42) 38 (26) 28 (30) 95 (32) 15 (36) 30 (24) 5 (31) 67 (36) 57 (36) 38 (49)
Unknown 0 0 0 0 0 0 1 (<1) 0 0 0 0 0 0
Time from diagnosis to
HCT, mo, median
(range)
8 (<1-82) 10 (3-62) 6 (2-108) .18 7 (<1-135) 7 (2-70) 6 (3-168) 6 (<1-177) 7 (3-54) 7 (2-86) .06 5 (2-49) 7 (2-313) 6 (2-58) 7 (2-36) .20
Conditioning regimen <.01 <.01 <.01
Bu þ Cy  other 46 (21) 7 (9) 28 (41) 13 (20) 16 (11) 34 (37) 118 (40) 15 (36) 48 (38) - - - -
TBI þ Cy  other 173 (79) 73 (91) 41 (59) 52 (80) 130 (89) 58 (63) 179 (60) 27 (64) 78 (62) - - - -
TBI þ Cy þ Flu  other - - - - - - - - - 9 (56) 152 (81) 1 (1) 0
TBI þ Flu  other
(no Cy)
- - - - - - - - - 0 2 (1) 30 (19) 21 (27)
Bu þ Flu  other - - - - - - - - - 1 (6) 1 (1) 101 (63) 42 (55)
Mel þ Flu  other - - - - - - - - - 6 (38) 33 (18) 28 (18) 14 (18)
TBI conditioning 173 (79) 73 (91) 41 (59) <.01 52 (80) 130 (89) 58 (63) 179 (60) 27 (64) 78 (62) <.01 9 (56) 154 (82) 31 (19) 21 (27) <.01
CMV status* <.01 <.01 <.01
Donor and recipient
negative
51 (23) 14 (18) 23 (33) 10 (15) 26 (18) 31 (34) 90 (30) 10 (24) 41 (33) 4 (25) 25 (13) 46 (29) 12 (16)
Donor or recipient
positive
138 (63) 48 (60) 45 (65) 49 (75) 99 (68) 58 (63) 203 (68) 32 (76) 84 (67) 10 (63) 126 (67) 112 (70) 62 (81)
Unknown 30 (14) 18 (23) 1 (1) 6 (9) 21 (14) 3 (3) 4 (1) 0 1 (1) 2 (13) 37 (20) 2 (1) 3 (4)
ATG before
transplantation
75 (34) 11 (14) 26 (38) <.01 47 (72) 132 (90) 79 (86) 238 (80) 27 (64) 81 (64) <.01 8 (50) 131 (70) 78 (49) 39 (51) <.01
Household income, $
(  1000), median
(range)y
52 (16-150) 51 (14-166) 48 (24-155) .47 61 (22-157) 52 (17-141) 53 (20-134) 57 (14-143) 53 (24-151) 54 (22-181) .11 65 (20-106) 55 (20-184) 60 (22-166) 55 (24-127) .42
* For double UCB recipients, donor is classiﬁed as CMV seropositive if either of the 2 units was CMV positive.
y Based on ZIP code of patient residence, from the 2011 US Census American Community Survey data.
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Figure 1. Number of days alive and out of the hospital in the ﬁrst 100 days
after allogeneic transplantation. (A) Pediatric MAC HCT recipients. (B) Adult
MAC HCT recipients. (C) Adult RIC HCT recipients. The lower and upper bars
represent the IQR (25th-75th percentile), and the middle bar represents the
median.
K.K. Ballen et al. / Biol Blood Marrow Transplant 20 (2014) 1819e18271822Patient ethnicity (Hispanic or non-Hispanic) and race (white, black,
Asian, American Indian/Alaska Native, Native Hawaiian/other Paciﬁc
Islander) are reported to the CIBMTR by transplantation centers according to
the US Ofﬁce of Management and Budget classiﬁcation [14-16]. Preparative
regimens were classiﬁed as MAC or RIC according to CIBMTR criteria [17,18].
HLA matching was performed at low resolution for class I and at high res-
olution for class II for UCB HCT, as are the majority of UCB transplants per-
formed in this era. In patients receiving a double-unit UCB transplant, the
worst match to the patient between the 2 units was used to categorize the
degree of recipienteUCB unit match. For MMUD and MUD HCT recipients,
high-resolution typing at HLA-A, -B, -C and -DRB1 was used.
Statistical Analysis
Summaries of patient-, disease-, and treatment-related characteristics
were generated for the various graft source groups. The chi-square test was
used to compare categorical variables, and the Kruskal-Wallis test was usedto compare continuous variables. Univariate probabilities of overall survival
were calculated using the Kaplan-Meier estimator [19].
Multivariate analysis was performed using Poisson regression. Overall
survival and LOS were similar in recipients of single UCB HCT and recipients
of double UCB HCT in all 3 groups analyzed, sowe combined the 2 categories
into a single category in multivariate analyses. We built 2 models. The ﬁrst
model considered the mean time (in days) that patients were alive and out
of the hospital within the ﬁrst 100 days after transplantation. Results are
summarized as means ratios for comparing groups; a means ratio >1 in-
dicates more days alive and out of the hospital. The second model examined
the proportion of days alive in the ﬁrst 100 days spent out of the hospital.
Results for bothmodels were similar, and thus only the former are presented
herein. Logistic regression models were used to assess 100-day mortality,
because there was no censoring before 100 days. (Deaths occurring at
day þ100 were treated as events.)
In addition to graft source, the patient and disease characteristic cova-
riates considered in the multivariate models included age, sex, recipient
race, Karnofsky performance status before transplantation, cytomegalovirus
(CMV) serologic status, HCT comorbidity index (HCT-CI) score, median
household income (imputed by patient ZIP code of residence based on the
2011 US Census American Community Survey data), diagnosis, and disease
status at transplantation. Information on patients’ insurance coverage was
not available and thus was not considered in the analysis.
All computations were performed using the SAS statistical package,
version 9.2 (SAS Institute, Cary, NC). All P values are 2-sided. A statistical
signiﬁcance level (a) of 0.05 was used throughout.
RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1. In the
pediatric MAC HCT recipients, there were differences among
the single UCB, double UCB, and MUD BM recipients in terms
of age, sex, race, diagnosis, CMV serostatus, conditioning
regimen, and exposure to antithymocyte globulin (ATG).
Double UCB recipients were older and were less likely to
receive ATG. Compared with MUD BM recipients, single and
double UCB recipients more frequently belonged to
nonwhite racial groups and received a TBI þ Cy-based con-
ditioning regimen. AML was more frequent in MUD BM re-
cipients compared with UCB recipients. Differences in
patient characteristics were seen in the same variables in
adult MAC and adult RIC recipients. In adults receiving MAC
HCT, UCB recipients were again more frequently nonwhite
andmore often received a TBIþ Cy-based regimen. Similarly,
in the adult RIC group, UCB recipients were more often
nonwhite. UCB recipients were also younger compared with
MUD PBSC and MMUD PBSC recipients. There were notable
differences in conditioning regimens, with UCB recipients
more likely to have received a TBI þ Cy þ Flu regimen. There
were no signiﬁcant differences among the various graft
sources considered in the 3 cohorts with respect to HCT-CI
score or patient socioeconomic status.
For the pediatric MAC group, the median total nucleated
cell dose (prefreeze) was 7  107/kg recipient weight for
single UCB recipients and 8  107/kg for double UCB re-
cipients. HLA 4/6-matched units were used in 29% of single
UCB and 46% of double UCB HCTs. Among adult MAC re-
cipients of single and double UCB transplants, the corre-
sponding median cell dose was 3  107/kg and 5  107/kg,
respectively, and HLA 4/6-matched units were used in 55%
and 68% of recipients, respectively. Among adult RIC re-
cipients, the median prefreeze total nucleated cell dose was
2  107/kg in both single and double UCB recipients. Some
44% of single UCB and 57% of double UCB transplants used
HLA 4/6-matched units.
Pediatric MAC HCT Group
Figure 1A shows the number of days alive and out of the
hospital in the ﬁrst 100 days after transplantation in
Table 2
Overall Survival at 100 Days, Results of Multivariate Analysis for Overall Mortality and Results of Multivariate Analysis Comparing the Number of Days Alive and
Out of the Hospital Among Graft Sources
Category n 100-Day Survival,
% (95% CI)
P Value* OR (95% CI) for
100-Day Mortality
P Valuey Means Ratio for Days
Alive and Out of Hospital
(95% CI)z
P Valuex
Pediatric MAC recipients .09 .28 .03
UCB{ 295 87 (83-91) 1.00 1.00
MUD BM 69 95 (89-100) 0.55 (0.18-1.63) 1.18 (1.02-1.36)
Adult MAC recipients <.001 <.001k <.001k
UCB{ 210 77 (73-83) 1.00 1.00
MUD BM 92 91 (86-97) 0.33 (0.15-0.73) .006 1.36 (1.21-1.54) <.001
MUD PBSC 296 90 (87-93) 0.37 (0.22-0.61) <.001 1.45 (1.32-1.59) <.001
MMUD BM 42 76 (64-90) 1.08 (0.49-2.36) .85 1.06 (0.89-1.26) .49
MMUD PBSC 126 77 (70-85) 1.04 (0.61-1.77) .88 1.19 (1.06-1.33) .003
Adult RIC recipients .002 <.001k <.001k
UCB{ 204 79 (74-85) 1.00 1.00
MUD PBSC 160 93 (89-97) 0.25 (0.12-0.50) <.001 1.38 (1.26-1.52) <.001
MMUD PBSC 77 87 (80-95) 0.43 (0.19-0.94) .03 1.33 (1.19-1.48) <.001
* Log-rank P value.
y Logistic regression P value.
z Means ratio compares the mean number of days that patients were alive and stayed out of the hospital in the ﬁrst 100 days after transplantation among the
graft sources considered and is adjusted for important patient characteristics; a means ratio >1 indicates a better outcome and longer duration alive and out of
the hospital; for example, in the pediatric MAC transplant group, recipients of MUD BM on an average, stayed 18% more days alive and out of the hospital
compared to UCB recipients.
x Poisson regression P value.
{ Single and double UCB were combined into a single category because the 100-day survival and days alive and out of the hospital were comparable.
k Overall P value.
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cohort. The median number was 50 days for single UCB,
54 days for double UCB, and 60 days for MUD BM (P ¼ .005).
Survival at 100 days for single and double UCB HCT recipients
was similar (88% [95% conﬁdence interval (CI), 83%-92%]
versus 85% [95% CI, 76%-92%]). Given the comparable LOS,
the 2 graft sources were combined into a single category for
multivariate analysis.
Table 2 presents the results of multivariate analysis.
Compared with UCB recipients, MUD BM recipients were
alive and out of the hospital for a signiﬁcantly longer dura-
tion in the ﬁrst 100 days after transplantation (means ratio,
1.18; P ¼ .03). We also identiﬁed other factors that were
signiﬁcantly associated with total hospital LOS. On average,
patients had fewer number of days alive and out of the
hospital if they were black (means ratio, 0.75 compared with
whites; P ¼ .01), had a Karnofsky Performance Status of <80
at HCT (means ratio, 0.63 compared with a score 80;
P ¼ .03) and were CMV seropositive (means ratio, 0.85;
P ¼ .006).
Table 3 presents days alive and out of hospital by selected
patient characteristics, such as recipient race, Karnofsky/
Lansky Performance Status at transplantation, HCT-CI score,
diagnosis, and median household income.
Overall, 43 patients (12%) died before day þ100 (39 UCB
recipients; 4 MUD BM recipients), 31 of whom (72%) stayed
in the hospital the entire time. Results of logistic regression
analysis showed no association between graft source and
mortality at 100 days post-transplantation (Table 2). We also
performed multivariate analysis for hospital LOS after
excluding these 43 patients. In this subset analysis of 100-
day survivors, UCB remained associated with fewer days
alive and out of the hospital.
Adult MAC HCT Group
We observed signiﬁcant differences in hospital LOS among
patients receiving each of the graft sources compared in this
cohort (Figure 1B). The median time alive and out of the
hospital in the ﬁrst 100 days was 52 days for single UCBrecipients, 55 days for double UCB recipients, 69 days forMUD
BM recipients, 75 days for MUD PBSC recipients, 63 days for
MMUD BM recipients, and 67 days for MMUD PBSC recipients
(P <.001). Single and double UCB recipients had comparable
survival at 100 days (74% [95% CI, 63-84%] and 79% [95% CI, 72-
85%]); similar to the pediatric analysis, given the similar
hospital LOS, here the 2 graft sources alsowere combined into
a single category for multivariate analysis.
Table 2 presents the results of multivariate analysis for
this cohort. There was no difference in the number of days
alive and out of the hospital between UCB and MMUD BM
recipients (means ratio, 1.06; P ¼ .49 compared with UCB).
However, compared with UCB recipients, the time alive and
out of the hospital in the ﬁrst 100 days was signiﬁcantly
greater for recipients of MUD BM (means ratio,1.36; P<.001),
MUD PBSCs (means ratio, 1.45; P <.001), and MMUD PBSCs
(means ratio, 1.19; P ¼ .003). In other pairwise comparisons,
MMUD BM recipients had a shorter time alive and out of the
hospital than recipients of either MUD BM (means ratio,
0.78; P ¼ .007) or MUD PBSCs (means ratio, 0.73; P <.001).
MMUD PBSC recipients also had fewer days alive and out of
the hospital compared with MUD BM (means ratio, 0.87;
P ¼ .03) and MUD PBSC (means ratio, 0.82; P <.001) re-
cipients. There was no signiﬁcant difference in 100-day LOS
between MMUD BM and MMUD PBSC recipients (means
ratio, 1.12; P ¼ .22) or between MUD BM and MUD PBSC re-
cipients (means ratio, 1.06; P ¼ .27). Shorter times alive and
out of the hospital were seen in black patients (means ratio,
0.72 compared with whites; P ¼ .03) and patients with ALL
(means ratio, 0.90 compared with AML; P ¼ .01). Patients age
25 years at HCT had a shorter LOS compared with those age
18-25 years at HCT (means ratio, 1.18; P ¼ .001). Table 3 re-
ports LOS by selected patient characteristics.
One hundered twenty-ﬁve patients (16%) died within the
ﬁrst 100 days post-transplantation, of whom 60 (48%) had
remained hospitalized the entire time. In logistic regression
analysis of 100-day mortality, UCB recipients were signiﬁ-
cantly more likely thanMUD BM andMUD PBSC recipients to
die during the ﬁrst 100 days (Table 2). In multivariate
Table 3
Number of Days Alive and Out of the Hospital in the First 100 Days after
Allogeneic HCT by Selected Patient Demographic Factors
Demographic Factor n Median Days
Alive and Out
of Hospital*
IQR P Valuey
Pediatric MAC HCT recipients
Recipient race .05
White 293 54 32-67
Black 35 38 0-61
Other 21 42 17-58
Unknown 19 53 29-66
Lansky score at
transplantation
.17
80 355 53 28-66
<80 11 19 7-48
Unknown 2 37 22-52
HCT-CI score .99
0 287 52 27-66
1-2 55 54 16-65
3 26 49 34-63
Diagnosis .35
AML 169 54 28-67
ALL 199 51 22-65
Median household
income, $z
.98
<50,000 165 53 31-65
50,000-100,000 167 51 21-67
100,000 20 53 40-61
Unknown 16 46 34-67
Adult MAC HCT recipients
Recipient race <.001
White 662 70 47-79
Black 53 48 21-68
Other 41 66 45-73
Unknown 12 64 54-80
Karnofsky score at
transplantation
.05
80 698 69 44-78
<80 59 54 38-80
Unknown 11 80 67-86
HCT-CI score .47
0 290 69 41-79
1-2 244 69 45-79
3 233 68 47-78
Diagnosis <.001
AML 568 70 52-79
ALL 200 60 29-76
Median household
income, $z
.18
<50,000 294 68 36-77
50,000-100,000 410 70 52-79
100,000 45 67 32-77
Unknown 19 68 44-80
Adult RIC HCT recipients
Recipient race .05
White 388 74 54-83
Black 22 70 43-78
Other 21 55 21-71
Unknown 10 72 24-78
Karnofsky score at
transplantation
.008
80 402 73 51-82
<80 33 74 57-85
Unknown 6 50 48-81
HCT-CI score .52
0 132 75 54-83
1-2 142 73 51-84
3 167 73 50-81
Diagnosis .43
AML 394 74 53-83
ALL 47 70 43-81
(Continued)
Table 3
(continued)
Demographic Factor n Median Days
Alive and Out
of Hospital*
IQR P Valuey
Median household
income, $z
.86
<50,000 159 74 48-85
50,000-100,000 237 71 53-81
100,000 33 76 59-82
Unknown 12 74 43-84
Data by graft source are presented in Figure 1.
* Larger number indicates more days alive and out of the hospital in the
ﬁrst 100 days after transplantation.
y Univariate P value.
z Based on ZIP code of patient residence (from the 2011 US Census
American Community Survey data).
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surviving >100 days, results were similar to the whole
cohort, with the number of days alive and out of the hospital
for UCB recipients comparable with that of MMUD BM re-
cipients, but signiﬁcantly less than that of MUD BM, MUD
PBSC, and MMUD PBSC recipients.
Adult RIC HCT Group
Figure 1C shows the days alive and out of the hospital for
this cohort (median, 65 days for single UCB recipients,
63 days for double UCB recipients, and 79 days for MUD PBSC
and MMUD PBSC recipients; P <.001). Four patients had no
reported inpatient days, presumably because they under-
went HCT as an outpatient procedure and did not require
subsequent hospitalization within the ﬁrst 100 days. Here
single and double UCB HCT were again combined into 1
category for multivariate analysis because of similar LOS and
100-day survival (75% [95% CI, 52%-92%] and 80% [95% CI,
74%-85%]).
In multivariate analysis, graft source was the sole variable
associated with number of days alive and out of the hospital
(Table 2). Compared with UCB recipients, the number of days
alive and out of the hospital was greater in recipients of MUD
PBSCs (means ratio, 1.38; P <.001) and MMUD PBSCs (means
ratio, 1.33; P <.001). There was no difference in hospital LOS
betweenMUD PBSC andMMUD PBSC recipients (means ratio
1.04; P ¼ .47). Table 3 reports days alive and out of the hos-
pital by selected patient characteristics for this cohort.
Sixty-four patients (15%) died within the ﬁrst 100 days, of
whom 24 (38%) had remained hospitalized the entire time.
Logistic regression analysis revealed an association between
graft source and 100-day mortality, with UCB recipients less
likely than MUD PBSC and MMUD PBSC recipients to survive
to 100 days (Table 2). Results of multivariate analysis of the
number of days alive and out of the hospital restricted to the
subgroup of 100-day survivors were similar to those seen for
the whole cohort.
DISCUSSION
In patients undergoing HCT without an HLA-matched
related donor, the decision to use one alternative graft
source over another is complex. Transplantation physicians
take several factors into consideration in selecting a graft
source, including the patient’s underlying disease, urgency of
K.K. Ballen et al. / Biol Blood Marrow Transplant 20 (2014) 1819e1827 1825need for transplantation, and donor availability. Little is
known about how resource needs compare across alternative
graft sources. Using a nationally representative and
contemporary cohort of patients, we show that the total
hospital LOS in the ﬁrst 100 days post-transplantation is
signiﬁcantly greater in pediatric and adult recipients of UCB
and MMUD HCT compared with recipients of MUD HCT.
Although resources generally do not ﬁgure directly in
decisions about graft source, our data have important policy
implications and will inform multiple stakeholders,
especially transplantation providers and centers, about the
resources needed to care for patients undergoing HCT from
alternative graft sources.
Hospital stay is the major driver of early post-transp
lantation resource use and costs, with an estimated 75%-
95% of total costs in the ﬁrst 100 days attributed to inpatient
stay [9-12,20-25]. We used total LOS in the ﬁrst 100 days for
our analysis (transplantation admission and any subsequent
admissions), because these data are captured by the CIBMTR.
To account for different rates of early mortality, we used the
number of days alive and out of the hospital in the ﬁrst
100 days as the endpoint of our analysis. Our ﬁnding of a
longer LOS in UCB recipients may reﬂect the fact these pa-
tients generally demonstrate later engraftment and usually
are hospitalized until neutrophil recovery occurs. In the adult
MAC HCT group, compared with UCB recipients, MMUD BM
recipients had a similar LOS and MMUD PBSC recipients had
a shorter LOS. In the adult RIC HCT group, UCB recipients had
a longer mean LOS in the ﬁrst 100 days compared with
MMUD PBSC recipients.
LOS, days alive and out of the hospital, and 100-day sur-
vival were similar in single and double UCB recipients in our
cohort of patients who underwent HCT in the recent era. This
likely reﬂects our understanding, developed over years of
research, that centers are able to appropriately select pa-
tients for single UCB versus double UCB HCT based on unit
cell dose and HLAmatch, withmany centers selecting double
UCB HCT if a single UCB unit of adequate cell dose is not
available. Our study was not designed to compare outcomes
of single versus double UCB HCT. Our results differ from a
recently published French study showing a lower relapse
rate, improved survival, and increased cost-effectiveness in
double UCB HCT compared with single UCB HCT in a cohort
of adult patients with acute leukemia [26].
There is considerable interest in comparing outcomes of
UCB HCT and haploidentical HCT. Parallel multicenter phase
II studies from the Blood and Marrow Transplant Clinical
Trials Network have shown a 1-year overall survival of 54%
and progression-free survival of 46% after UCB HCT, with
corresponding rates of 62% and 48% after haploidentical BM
HCT [27]. An ongoingmulticenter randomized phase III study
through the Network is comparing outcomes between these
2 graft sources. As part of our original study question, we
were interested in comparing LOS in UCB HCT and hap-
loidentical HCT; however, we were not able to include hap-
loidentical HCT in our analysis because of the small number
of patients. (Only 41 patients reported to the CIBMTR be-
tween 2008 and 2011 had received HCT using an “other
relative” donor source and met the other study selection
criteria.) As more experience with haploidentical HCT is
attained, assessment of its associated costs and resource
needs compared with other donor sources will be of para-
mount importance.
An interesting observation is the longer hospital LOS in
black children and adults who received MAC conditioning,which persisted even after adjusting for other patient and
disease characteristics. Although our study was not designed
speciﬁcally to study the association of race with outcomes,
black pediatric MAC HCT recipients (but not adult recipients)
had signiﬁcantly higher 100-day mortality compared with
whites on logistic multivariate regression analysis. It is well
known that the use of UCB increases access to HCT, and that
UCB is more likely to be used in black patients, who
frequently lack other suitable donor sources [28-30]. Previ-
ous studies also have shown an association between race and
outcomes of allogeneic HCT, including those after single UCB
transplantation [15,16,28]. Black recipients of single UCB HCT
are also more likely thanwhites to receive UCB units that are
smaller and less well matched [16], which may inﬂuence the
time to engraftment and consequently the hospital LOS.
Thus, such factors as health care disparities and availability of
a suitable donor (eg, adequate UCB units) may help explain
our ﬁnding of a raceehospitalization association. The
observation of racial/ethnic differences in LOS requires more
detailed examination in future studies.
We considered patient socioeconomic status in our
analysis using median household income based on ZIP code
of residence. Socioeconomic status is a surrogate for several
healthcare status indicators, including insurance status [31].
We did not ﬁnd an association between socioeconomic sta-
tus and LOS or 100-day mortality. It is possible that biological
factors (eg, lower cell dose for UCB units) may contribute to
the longer LOS seen in black patients; however, the number
of patients was too small for us to analyze an association
between socioeconomic factors and LOS within each racial/
ethnic subgroup.
This study has some limitations. Patients were treated at
numerous different centers using various conditioning and
GVHD prophylaxis regimens. We restricted our study to pa-
tients with acute leukemia in ﬁrst or second CR or CR and to
commonly used conditioning and GVHD prophylaxis regi-
mens, to establish a relatively homogenous cohort. We were
not able to account for variations in transplantation center
practices [32,33], which could inﬂuence the hospital LOS for
patients. In addition, the CIBMTR does not collect informa-
tion on caregiver and community support, which also may
inﬂuence LOS. Only 4 patients underwent outpatient HCT
without the need for hospital admission during the ﬁrst
100 days. Our study was limited to patients who underwent
transplantation in the United States. We were not able to
consider patient payor type and quality of insurance
coverage, which could affect LOS after transplantation; for
example, hospital LOS has been shown to be longer in
Medicaid patients in other medical situations [34]. Medicare
patients may have additional pressure to limit LOS. We were
not able to account for important pretransplantation cost
and resource factors (eg, costs of graft acquisition). Also, our
study focused on hospitalizations over the ﬁrst 100 days
post-transplantation and was not able to account for later
hospitalizations and resource utilization. Chronic GVHD and
relapsed disease incur signiﬁcant costs to the health care
system, but were beyond the scope of this study. For
example, chronic GVHD may be less prevalent among UCB
recipients compared with recipients of other graft sources
[1,6], which in turn may be associated with lower long-term
costs and resource needs.
In conclusion, we comprehensively examined the hospital
LOS in the ﬁrst 100 days post-transplantation in patients
undergoing HCT from alternative graft sources. We found an
extended LOS for recipients of all of these alternative graft
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ment, decrease infection, and improve home monitoring
need to be developed to decrease LOS. The use of double UCB
grafts was not associated with shorter LOS. The use of UCB
was associated with a longer LOS compared with the other
alternative graft sources analyzed in both pediatric and adult
patients. These data will aid transplantation providers and
centers in understanding the expected resources needed to
treat individual HCT recipients, develop strategies to reduce
LOS, and select the graft source likely to have the best
outcome and be the most cost-effective. Future studies are
needed to elucidate factors that may account for differential
LOS among alternative graft sources, such as rates of infec-
tion, GVHD and engraftment, and to address interventions to
reduce the duration of hospitalization in general.ACKNOWLEDGMENTS
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